UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma

The purpose of this research study is to find out what effects, good and/or bad, there are to treating papillary kidney cancer with an investigational agent, ARQ 197, or a combination of ARQ 197 with erlotinib. ARQ 197 is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of papillary kidney cancer. Erlotinib is an investigational drug that has been approved by the FDA for the treatment of lung cancer but is not approved for the treatment of papillary kidney cancer. The combination of these two drugs (ARQ 197 and erlotinib) is also considered investigational.

Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. About 78 people will participate in this study nationwide.

Start Date
November 2, 2012
End Date
November 2, 2022
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Clarine Halvorsen, 319-356-3944

ARQ 197 ; cancer ; erlotinib ; IRB#201210747 ; papillary kidney cancer ; phase II ; phase two ; SWOG S1107 ; vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.